Clinical Trial

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Study acronym: ELDORADO
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple myeloma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Trial Details
NCT Number NCT07247097
Lead Sponsor Massachusetts General Hospital
Collaborators: Pfizer
Conditions Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Enrollment 160 participants
Start Date 2026-08-01
Primary Completion 2030-12-01 (estimated)
Study Completion 2035-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-23